The emerging pharmaceutical and biotech industry is thriving. Between 2006 and 2015, 105 companies - the majority of which were in the USA - launched a product for the first time. And, over 60% of those products were originally discovered in universities and small biotech companies.
All such pre-commercial companies must make a fundamental decision at some point in the drug development process: is it more advantageous to take the product to market on our own or to partner with an established large pharmaceutical company? This decision is typically made as developers approach the end of Phase II clinical trials, but can take place at any time - even after the drug has launched.
Recognizing the dilemma, QuintilesIMS analyzed the approaches of companies that launched products for the first time between 2006 and 2015 to understand their funding/commercialization strategies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze